Table 1

Patient characteristics (n = 26)

*Mean (standard deviation).
†Median (interquartile range).
‡Expressed as total levodopa equivalent dose: 100 levodopa equivalents = 100 mg standard levodopa = 133 mg controlled release levodopa = 10 mg bromocriptine = 5 mg ropinirole = 1 mg pramipexole = 1 mg cabergoline = 2 mg apomorphine. For patients who received a COMT inhibitor, the sum of standard levodopa and 0.75 times the dose of controlled release levodopa was multiplied by 1.3.19–21
§Sum score of the dyskinesia part (items 32–35) of section IV (complications of therapy) of the UPDRS (possible score range, 0–13).1
¶Sum score of the clinical fluctuations part (items 36–39) of section IV (complications of therapy) of the UPDRS (possible score range, 0–7).1
**Sum score of the mini-mental state examination (possible score range, 0–30).13
M, male; F, female; MMSE, mini-mental state examination; PD, Parkinson’s disease; UPDRS, unified Parkinson’s disease rating scale.
Sex (M:F)15:11
Age (years)62.8 (7.5)*
Time since PD diagnosed (years)13.8 (4.3)*
Hoehn and Yahr stage of PD (during “off”)IV (III-V)†
Daily antiparkinsonian drug treatment‡1877 (1645)*
Dyskinesia score (UPDRS IV; 0–13)§5 (3 to 7)†
Fluctuation score (UPDRS IV; 0–7)¶4 (2 to 4)†
MMSE score (0–30)**29 (28 to 30)†